Biovitrum AB (publ)
Records under this name other than patents Biovitrum AB (publ) holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,304,387 | Therapeutic Formulations of Keratinocyte Growth Factor Formerly held In force · High confidence | In force | High confidence | |
| US 6,465,467 | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases Formerly held Term ended Term ended May 19, 2020 · From the USPTO record | Term ended | Term ended May 19, 2020 | From the USPTO record |
| US 8,030,316 | Malate salt of (2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine Formerly held Lapsed on the fee record Ended Oct 4, 2019 · From the USPTO record | Lapsed on the fee record | Ended Oct 4, 2019 | From the USPTO record |
| US 7,129,354 | Process for the preparation of stable acid addition salt of 2,3-disubstituted pyrazine compounds Formerly held Lapsed on the fee record Ended Oct 31, 2018 · From the USPTO record | Lapsed on the fee record | Ended Oct 31, 2018 | From the USPTO record |
| US 7,820,677 | Phosphoric acid addition salt of (2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}-ethoxy)-2-pyrazinyl]-2-methylpiperazine Formerly held Lapsed on the fee record Ended Oct 26, 2018 · From the USPTO record | Lapsed on the fee record | Ended Oct 26, 2018 | From the USPTO record |
| US 7,812,017 | 4-substituted indole and indoline compounds Formerly held Lapsed on the fee record Ended Oct 12, 2018 · From the USPTO record | Lapsed on the fee record | Ended Oct 12, 2018 | From the USPTO record |
| US 8,835,439 | Pharmaceutical composition containing (2R)-methyl-1-3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinylpiperazine L-malate for treatment of serotonin-related diseases Formerly held Lapsed on the fee record Ended Sep 16, 2018 · From the USPTO record | Lapsed on the fee record | Ended Sep 16, 2018 | From the USPTO record |
| US 7,071,180 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases Formerly held Lapsed on the fee record Ended Jul 4, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jul 4, 2018 | From the USPTO record |
| US 6,248,319 | Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides Term ended Term ended Jun 19, 2018 · From the USPTO record | Term ended | Term ended Jun 19, 2018 | From the USPTO record |
| US 6,218,148 | DNS encoding stem cell factor Term ended Term ended Apr 17, 2018 · From the USPTO record | Term ended | Term ended Apr 17, 2018 | From the USPTO record |